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AERD = aspirin-exacerbated respiratory disease; COX = cyclooxygenase; cys-LT = cysteinyl leukotriene; LT = leukotriene; NSAIDs = non-steroidal
anti-inflammatory drugs; PG = prostaglandin.
Available online http://arthritis-research.com/content/5/1/25
Introduction
Up to 10–20% of the general asthmatic population have
hypersensitivity to aspirin and non-steroidal anti-inflamma-
tory drugs (NSAIDs) leading to severe exacerbation of
asthma and naso-ocular reactions [1,2]. Formerly termed
aspirin-sensitive asthma, these patients are now character-
ized as having aspirin-exacerbated respiratory disease
(AERD) because they have chronic upper and lower respi-
ratory-tract mucosal inflammation, sinusitis, nasal polypo-
sis, and asthma independent of their hypersensitivity
reactions [3]. Because essentially all traditional NSAIDs
also trigger the hypersensitivity reaction, treatment of pain
and inflammation has been challenging. With the introduc-
tion of drugs that specifically inhibit cyclooxygenase
(COX)-2, the question of whether these agents cross-
react with aspirin to cause exacerbation of asthma and
rhinitis becomes clinically relevant.
Eicosanoids are important mediators of bronchial reactiv-
ity and inflammation in asthma. In the asthmatic airway,
arachidonic acid is metabolized to prostaglandins (PGs)
and leukotrienes. PGE2 functions as a bronchodilator and
can also inhibit granulocyte functions [4]. PGs are pro-
duced through an enzymatic pathway that includes the
COX enzymes. Both the COX-1 and COX-2 isoforms are
expressed in the respiratory epithelium (basal and ciliated
cells) in normal subjects and in patients with chronic
stable asthma and chronic bronchitis [5]. Epithelial
COX-1 expression is not different in asthmatics with or
without aspirin sensitivity and in normal subjects, whereas
COX-2 expression is increased in asthmatics compared
with normals but is not different in aspirin-sensitive asth-
matics compared with aspirin-tolerant asthmatics [4,6].
However, COX-2-expressing inflammatory cells are
increased in the submucosa of aspirin-sensitive asthmat-
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Abstract
The use of analgesic anti-inflammatory agents in patients with asthma is clinically challenging because
of the prevalence (10–20%) of aspirin hypersensitivity. Aspirin-exacerbated respiratory disease
(AERD), or aspirin-induced asthma, is characterized by asthma and rhinitis triggered by the ingestion of
aspirin and non-steroidal anti-inflammatory drugs. AERD is associated with upper and lower
respiratory-tract mucosal inflammation, progressive sinusitis, nasal polyposis, and asthma regardless of
whether patients avoid triggering drugs. The mechanism underlying the propensity of aspirin and non-
steroidal anti-inflammatory drugs to cause this reaction is thought to involve inhibition of the synthesis
of protective prostaglandins (PGs), resulting in an increase in the synthesis of cysteinyl leukotrienes by
eosinophils and mast cells. Clinical data suggest that protective PGs are derived from cyclooxygenase
(COX)-1 because studies have now confirmed that drugs specifically inhibiting COX-2 are not cross-
reactive with aspirin in patients with AERD.
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ics [6]. Furthermore, COX-2 expression is increased in
airway epithelium in non-corticosteroid-treated asthmatics
compared with steroid-treated asthmatics and non-asth-
matic controls [7].
Although COX expression does not consistently distin-
guish aspirin-sensitive from aspirin-tolerant asthmatics, a
marked increase in expression of leukotriene C4 (LTC4)
synthase in aspirin-sensitive asthmatics has been demon-
strated [4]. The cysteinyl leukotrienes (cys-LTs) are potent
bronchoconstrictors synthesized by the 5-lipoxygenase
and the LTC4 synthase enzyme pathways of hematopoietic
cells [4]. In asthmatics with aspirin sensitivity there is a
large increase in cys-LT production after exposure aspirin,
and LT synthesis inhibitors and selective cys-LT receptor
antagonists markedly attenuate aspirin-induced respiratory
reactions [4]. This leads to the hypothesis that the aspirin-
and NSAID-mediated inhibition of PGE2 production
releases a ‘brake’ on cys-LT synthesis by eosinophils and
mast cells, leading to marked overproduction that medi-
ates symptom exacerbation [4].
COX-2 inhibitors in asthma
The hypothesis that PGE2 production in the setting of
AERD is derived from a COX-1-dependent pathway is
based chiefly on the clinical observation that selective
inhibitors of COX-2 have not been reported to cross-react
with aspirin in these patients. Initially, it was reported that
relatively selective COX-2 inhibitors such as nimesulide
and meloxicam had a reduced propensity to cross-react
with aspirin in patients with AERD, particularly at low
doses [3]. Several studies have now been reported to
determine rigorously whether the specific COX-2
inhibitors rofecoxib and celecoxib trigger asthma exacer-
bation or naso-ocular symptoms in patients with AERD
(Table 1) [3,8–10].
The most recent of these studies was reported by
Woessner  et al. [3]. Sixty asthmatic patients with a
history of AERD completed a double-blind placebo-con-
trolled challenge with 100 and 200mg of celecoxib over
2 days, followed by an aspirin challenge to confirm the
clinical history. All subjects exhibited adverse responses
to aspirin, but no subject developed either a significant
change in FEV1 (forced expiratory volume in 1s) or in the
naso-ocular symptom score. The confidence interval for
the probability of celecoxib inducing cross-reactions with
aspirin in AERD patients was calculated to be between
0% and 5%. All subjects had a very clear history of
AERD and demonstrated symptoms in response to
aspirin on the day after absence of response to cele-
coxib, demonstrating a lack of desensitization. All sub-
jects were allowed to remain on corticosteroids (nasal,
inhaled, and systemic) and leukotriene modifiers, elimi-
nating the confounder of withdrawing symptom-control-
ling medications.
Conclusions
Studies from several different laboratories have now con-
cluded that the specific COX-2 inhibitors rofecoxib and
celecoxib do not cross-react with aspirin and NSAIDs to
cause exacerbation of asthma or naso-ocular symptoms in
patients with AERD. These studies suggest that inhibition
of COX-1 is required to trigger the increased cys-LT pro-
duction associated with asthma exacerbation. However,
the mechanism by which COX-1, but not COX-2, inhibi-
tion might cause this response remains unclear. Although
these studies were performed as challenge tests rather
than as long-term placebo-controlled trials, they are con-
vincing. The fact that specific COX-2 inhibitors seem safe
in AERD does not imply that other hypersensitivity reac-
tions do not occur.
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Table 1
Specific COX-2 inhibitors in patients with aspirin-exacerbated
respiratory disorders (aspirin-induced asthma)
Study COX-2 Number Adverse Aspirin
inhibitor of patients reaction* response
Woessner et al. [3] Celecoxib 60 No Yes
Dahlen et al. [9] Celecoxib 27 No Not
tested
Szczeklik et al. [8] Rofecoxib 12 No Yes
Stevenson et al. [10] Rofecoxib 60 No Yes
* Decrease in FEV1 (forced expiratory volume in 1s) and/or induced
naso-ocular symptoms.27
9.  Dahlen B, Szczeklik A, Murray JJ: Celecoxib in patients with
asthma and aspirin intolerance. New Engl J Med 2001, 344:
142.
10. Stevenson DD, Simon RA: Lack of cross-reactivity between
rofecoxib and aspirin in aspirin-sensitive patients with
asthma. J Allergy Clin Immunol 2001, 108:47-51.
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